CA2093928A1 - Anticorps monoclonaux pour la detection et le traitement due cancer - Google Patents

Anticorps monoclonaux pour la detection et le traitement due cancer

Info

Publication number
CA2093928A1
CA2093928A1 CA2093928A CA2093928A CA2093928A1 CA 2093928 A1 CA2093928 A1 CA 2093928A1 CA 2093928 A CA2093928 A CA 2093928A CA 2093928 A CA2093928 A CA 2093928A CA 2093928 A1 CA2093928 A1 CA 2093928A1
Authority
CA
Canada
Prior art keywords
cancer
treatment
detection
monoclonal antibodies
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2093928A
Other languages
English (en)
Other versions
CA2093928C (fr
Inventor
Mark C. Willingham
Kai Chang
Ira H. Pastan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
Mark C. Willingham
Kai Chang
Ira H. Pastan
The United States Of America, Represented By The Secretary, U.S. Departm Ent Of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark C. Willingham, Kai Chang, Ira H. Pastan, The United States Of America, Represented By The Secretary, U.S. Departm Ent Of Commerce filed Critical Mark C. Willingham
Publication of CA2093928A1 publication Critical patent/CA2093928A1/fr
Application granted granted Critical
Publication of CA2093928C publication Critical patent/CA2093928C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention se rapporte à un anticorps monoclonal, appelé K1, et à ses utilisations. En particulier, l'anticorps monoclonal peut être utilisé comme agent de ciblage thérapeutique dans le traitment et le diagnostic de nombreuses formes de cancer.
CA002093928A 1990-10-12 1991-10-09 Anticorps monoclonaux pour la detection et le traitement due cancer Expired - Lifetime CA2093928C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59629190A 1990-10-12 1990-10-12
US596,291 1990-10-12
PCT/US1991/007227 WO1992007081A2 (fr) 1990-10-12 1991-10-09 Anticorps monoclonal

Publications (2)

Publication Number Publication Date
CA2093928A1 true CA2093928A1 (fr) 1992-04-13
CA2093928C CA2093928C (fr) 2000-02-29

Family

ID=24386742

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002093928A Expired - Lifetime CA2093928C (fr) 1990-10-12 1991-10-09 Anticorps monoclonaux pour la detection et le traitement due cancer

Country Status (10)

Country Link
US (3) US5320956A (fr)
EP (1) EP0554356B1 (fr)
JP (1) JP2660241B2 (fr)
AT (1) ATE171207T1 (fr)
AU (1) AU648363B2 (fr)
CA (1) CA2093928C (fr)
DE (1) DE69130224T2 (fr)
DK (1) DK0554356T3 (fr)
ES (1) ES2121792T3 (fr)
WO (1) WO1992007081A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
SE9501302D0 (sv) * 1995-04-07 1995-04-07 Bioinvent Internatioal Ab Antibodies for use in cancertherapy and diagnosis
US5871941A (en) * 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
US7375183B1 (en) 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
EP0871492B1 (fr) * 1996-01-05 2003-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Antigene de mesothelium, procedes et kits de ciblage de celui-ci
US6406917B1 (en) 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US5919643A (en) 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
DE69833459T2 (de) * 1997-12-01 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
CA2369433A1 (fr) * 1999-02-26 2000-08-31 Pacific Northwest Research Institute Techniques et compositions pour le diagnostic de carcinomes
US7745159B2 (en) * 1999-02-26 2010-06-29 Nathalie B Scholler Methods and compositions for diagnosing carcinomas
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
DK1180123T3 (da) 1999-05-27 2008-10-13 Us Gov Health & Human Serv Immunkonjugater, der har höj bindingsaffinitet
US6987024B1 (en) * 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
WO2004006837A2 (fr) * 2002-07-12 2004-01-22 The Johns Hopkins University Vaccins a la mesotheline et systemes de modele
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20060014221A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
WO2005072341A2 (fr) 2004-01-21 2005-08-11 Fujirebio America, Inc. Detection de peptides du type mesotheline / facteur de potentiation des megacaryocytes dans le fluide peritoneal pour evaluer le peritoine et la cavite peritoneale
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2006005065A2 (fr) * 2004-06-30 2006-01-12 University Of South Florida Caracterisation de la luminescence de points quantiques conjugues a des biomarqueurs pour une detection precoce de cancer
WO2006099141A2 (fr) 2005-03-10 2006-09-21 Morphotek, Inc. Anticorps diriges contre la mesotheline
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
PL2195017T3 (pl) 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
WO2015123654A1 (fr) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Nanoparticules amine-passivées pour le traitement et l'imagerie du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666845A (en) * 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
JPH0763389B2 (ja) * 1986-10-28 1995-07-12 協和醗酵工業株式会社 抗ヒト中皮細胞単クローン性抗体
EP0377657A1 (fr) * 1987-08-19 1990-07-18 Centocor, Inc. Antigene associe a des tumeurs des ovaires humains specifique de l'anticorps monoclonal ov-tl3
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors

Also Published As

Publication number Publication date
US5525337A (en) 1996-06-11
WO1992007081A2 (fr) 1992-04-30
EP0554356A1 (fr) 1993-08-11
DE69130224D1 (de) 1998-10-22
JPH06506824A (ja) 1994-08-04
US5320956A (en) 1994-06-14
EP0554356A4 (en) 1993-09-15
AU8921991A (en) 1992-05-20
EP0554356B1 (fr) 1998-09-16
JP2660241B2 (ja) 1997-10-08
DE69130224T2 (de) 1999-05-06
CA2093928C (fr) 2000-02-29
ATE171207T1 (de) 1998-10-15
AU648363B2 (en) 1994-04-21
US5817313A (en) 1998-10-06
DK0554356T3 (da) 1999-06-14
ES2121792T3 (es) 1998-12-16

Similar Documents

Publication Publication Date Title
CA2093928A1 (fr) Anticorps monoclonaux pour la detection et le traitement due cancer
CA2249320A1 (fr) Anticorps humanises glycosyles specifiques des lymphocytes b
CA2149329A1 (fr) Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
CA2041260A1 (fr) Agents de contraste ultrasonore, leur procede de preparation et leur utilisation en tant qu'agents de diagnostic et de traitement
CA2210751A1 (fr) Anticorps monoclonaux anti-cd6 et ses utilisations
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
CA2182289A1 (fr) Anticorps monoclonaux immunostimulants
EP0671920A4 (fr) Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih.
CA2093667A1 (fr) Anticorps monoclonaux murins et leur utilisation
CA2133106A1 (fr) Anticorps monoclonaux contre le recepteur de l'interferon a action neutralisant l'interferon de type i
PL317536A1 (en) Monoclonal antibody against cd 44v6
CA2137561A1 (fr) Photoactivation de proteines en vue de leur conjugaison
CA2212150A1 (fr) Anticorps monoclonaux contre des antigenes de surface de cellules osteogenes
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
EP0672253A4 (fr) Antigene (sk1) associe au carcinome et anticorps monoclonaux diriges contre le sk1, procedes de production de ces anticorps et applications.
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
EP0232871A3 (fr) Anticorps monoclonal humain, hybridome le produisant et son utilisation
CA2316411A1 (fr) Anticorps humanises monoclonaux protegeant contre les maladies induites par les toxines de shiga
AU8866791A (en) Monoclonal antibody for use in diagnosing alzheimer's disease, hybridoma secreting said antibody and preparation method therefor
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
CA2139518A1 (fr) Regions antigeniques des complexes de particules liberes par les tumeurs et anticorps
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
CA2091967A1 (fr) Anticorps anti-ganglioside monoclonal, sa preparation et son utilisation comme agent therapeutique pour le traitement des tumeurs

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry